Terlipressin Acetate /(CAS 14636-12-5)/Pharmaceutical

Terlipressin Acetate (CAS 14636-12-5) is a high-purity synthetic vasopressin analog, engineered with exceptional stability and targeted bioactivity for critical clinical applications. As a potent vasoconstrictor, it selectively constricts splanchnic blood vessels to reduce portal venous pressure, making it a first-line choice for managing acute esophageal and gastric variceal bleeding caused by cirrhosis. Its advanced molecular structure ensures a longer duration of action compared to natural vasopressin, minimizing the need for frequent dosing and enhancing treatment compliance. Produced under strict GMP standards, this pharmaceutical-grade compound guarantees batch-to-batch consistency, with purity levels exceeding 99% verified by HPLC and NMR testing.

Tailored for hospital pharmacies, clinical research institutions, and biopharmaceutical manufacturers, Terlipressin Acetate delivers reliable performance in emergency care settings and experimental studies alike. Beyond variceal bleeding management, it also demonstrates remarkable efficacy in improving renal perfusion for patients with hepatorenal syndrome, addressing unmet medical needs in critical care. For buyers prioritizing safety, efficacy, and regulatory compliance, this product stands out as a cost-effective solution—backed by comprehensive COA documentation and customizable packaging options to meet bulk or small-batch order requirements. Its proven track record in clinical practice and adherence to international quality benchmarks make it an indispensable addition to any pharmaceutical supply chain.